Calithera Biosciences Inc. (CALA) Trading Up 2.4%
Calithera Biosciences Inc. (NASDAQ:CALA)’s share price was up 2.4% during trading on Wednesday . The stock traded as high as $3.53 and last traded at $3.46, with a volume of 236,655 shares trading hands. The stock had previously closed at $3.38.
Several equities analysts recently commented on CALA shares. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research note on Tuesday, March 22nd. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Wednesday, June 8th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research note on Thursday, May 12th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.48.
The company’s market capitalization is $64.64 million. The stock’s 50 day moving average is $4.46 and its 200 day moving average is $5.31.
Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.05. Equities research analysts anticipate that Calithera Biosciences Inc. will post ($2.15) EPS for the current year.
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.